You are here: Home :: Area NEM :: Medical science :: Human medicine :: Internal medicine

I. Bodendiek, S. Lentz, M. Seeger, H. D. Bruhn

Chromogenic substrate as antidote against the thrombin inhibitor Melagatran?

It could be shown in vitro that a chromogenic substrate (Chromozym TH, Roche Mannheim) acts at least partially as antidote against the new thrombin inhibitor Melagatran (AstraZeneca, Mlndal, Sweden). It is discussed that this antidote effect of a chromogenic substrate might be due to a substrate competition of fibrinogen, thrombin inhibitor, and chromogenic substrate for thrombin. Further animal experiments will clarify whether this in vitro observation is of practical relevance in vivo, too.

Hämostaseologie, Schattauer

Print ISSN: 0720-9355
Volume: 23, 01/2003
Pages: 97 - 98

Show full article (external site)

Show all available items of this journal

 

Area NEM